The international multicenter registry aims to gather real-world data on patient outcomes and assess the procedural success and performance of various device occluders used in the transcatheter treatment of pediatric and adult patients with perimembranous ventricular septal defects (PmVSD).
Who can participate
Age range3 Months
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients with perimembranous ventricular septal defects (PmVSD), as defined by 2D transthoracic echocardiography according to previously published classifications.
✓. Defect size between 3 mm and \<20 mm on the left ventricular side, as measured by 2D echocardiography.
✓. Left-to-right ventricular shunt.
✓. Age ≥3 months and body weight≥5 kg.
✓. Symptomatic patients (heart failure, failure to thrive, recurrent respiratory infections, and rest or exercise dyspnea) or asymptomatic patients with progressive heart enlargement.
✓. History of infective endocarditis related to the PmVSD or hemodynamically significant PmVSD with: Qp/Qs \>1.5 on catheterization, left ventricular volume overload (LVEDD z-score \>2) based on echocardiography, or pulmonary hypertension on catheterization (mean pulmonary artery pressure \>20 mmHg).
✓. Presence or absence of aortic valve prolapse, with or without regurgitation.
✓. Presence or absence of a membranous septal aneurysm, with or without inlet or outlet extension.
Exclusion criteria
✕. Eisenmenger physiology (pulmonary vascular resistance \> 8 Wood units, nonreactive) with an exclusive right-to-left shunt.
✕. Pre-existing complete heart block or high-risk proximity of the conduction system to the defect without prior pacemaker implantation.